Literature DB >> 15583827

Expression of thrombospondin-1 in prostate-derived cell lines.

Manuela Bastian1, Michael Steiner, Peter Schuff-Werner.   

Abstract

Thrombospondin-1 (TSP-1) is a multifunctional matricellular glycoprotein involved in several mechanisms critical to the formation and progression of solid tumors including cell adhesion, proliferation, migration, invasion, and angiogenesis. However, work related to TSP-1 expression and functionality in prostate cancer is limited. Expression experiments in the present study demonstrated lower expression of TSP-1 in the prostate cancer cell lines DU 145 and LNCaP compared to SV40-immortalized prostatic epithelial cells PNT 1A. All three cell lines expressed the TSP-1 receptor CD36. Exogenously added TSP-1 modulated the cellular phenotype of LNCaP cells, which demonstrated decreased proliferation rate and partly entered apoptosis. Collectively, these data support the concept that partial or complete loss of TSP-1 synthesis may provide tumor cells with a proliferation advantage. In addition, TSP-1 located at the border between tumor and stroma as observed in primary prostate tumors may act as a barrier of tumor growth depending on the TSP-1 receptor repertoire of the tumor cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15583827

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

1.  Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.

Authors:  Philip P Fitchev; Susan M Wcislak; Chung Lee; Anders Bergh; Charles B Brendler; Veronica M Stellmach; Susan E Crawford; Constantine D Mavroudis; Mona L Cornwell; Jennifer A Doll
Journal:  Lab Invest       Date:  2010-05-10       Impact factor: 5.662

2.  Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6.

Authors:  Janeen Azare; Kenneth Leslie; Hikmat Al-Ahmadie; William Gerald; Paul H Weinreb; Shelia M Violette; Jacqueline Bromberg
Journal:  Mol Cell Biol       Date:  2007-04-16       Impact factor: 4.272

3.  Ezetimibe is an inhibitor of tumor angiogenesis.

Authors:  Keith R Solomon; Kristine Pelton; Kelly Boucher; Jinsoo Joo; Christopher Tully; David Zurakowski; Carl P Schaffner; Jayoung Kim; Michael R Freeman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

4.  Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

Authors:  Jeff S Isenberg; Fuminori Hyodo; Lisa A Ridnour; Caitlin S Shannon; David A Wink; Murali C Krishna; David D Roberts
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

Review 5.  Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2013-06-07       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.